Inhibitors of SGLT2 have been shown to reduce MACE in patients with type 2 DM and established cardiovascular disease. In patients with chronic kidney disease at risk of progression, SGLT2 inhibitors have shown reduction in risk of eGFR decline and hospitalization. In SLE, clinical trials have yet to explore the possible role of SGLT2i in improving renal outcomes in lupus nephritis. A couple of abstracts presented during the meeting tackled the topic of SGLT2 inhibition in SLE.
All News
Article
Article
Adult-onset Still’s disease (AOSD) is a rare complex, sporadic, systemic autoinflammatory disease similar to systemic juvenile idiopathic arthritis (sJIA) characterized by sustained fever, salmon-colored rash, and arthritis.
Article
Our reporters have been prolific in finding the hot abstracts, those that were most attended or those that are getting the most buzz on social media. Here are RheumNow's #ACRbest abstract reports from Monday, November 13, 2023 at #ACR23, covering The Great Debate, SGLPT2 inhibitors in SLE, the SMART Study of MTX, TMP/SMX Prophylaxis, RA-ILD & TNF Inhibitors, cancer research and more.
sheila
Tweet
Retrospective database study from Japan of PsA pts:
At 12/24 mos ffg tx initiation, 37.5%/49% of pts discontinued index bDMARD while 22.2%/31.2% switched tx.
Dc rates lowest for risankizumab
🤔Reasons for switching/discontinuation not mentioned.
#ACR23 ABST2246 @RheumNow https://t.co/6dhKZmp1wE
Eric Dein
Tweet
Later today at #ACR23 at 4pm
See Ab#2545 on IV secukinumab for AxSpA
Read about it now on @RheumNow:
https://t.co/s9IinpVxgR
The Fallacy of Biologic Treatment to Prevent RA
It is time to stop fooling ourselves that we can prevent RA with our existing biologic agents. #ACR23
https://t.co/qHMW4HGkk2 https://t.co/l2Tn7hGtY3
Robert B Chao, MD
Tweet
Gender differences in switching biologics in PsA pts
Women had higher biologic switch rates, mainly due to lack of efficacy
Other gender specific factors include gestational reasons and different sociodemographic features
@RheumNow #ACR23 Abs#2247 https://t.co/mLm183fCBw
David Liew
Tweet
If we're to summarize the challenges to making for CAR-T therapy work in a given disease, this is it:
Dr. Chyi-Song Hsieh @WUSTL #ACR23 @RheumNow https://t.co/raoHtrJ25S
Dr. Rachel Tate
Tweet
Vaccination appears to be effective and safe post CAR-T treatment. This sets the stage for better understanding of the patient experience. Dr. Schett #ACR23 @RheumNow https://t.co/OQCNTt5wPh
Janet Pope
Tweet
#ACR23 highlights from PlenaryII
🙉#RA #ILD seems that #TNFi is equal to other bDMARDs - was thought to worsen /cause it.
🙉Septra should be given with #rituximab and #steroids in #GCA to prevent #infections not just #PJP
#ACR23 @RheumNow @ACRheum #ACRbest
Janet Pope
Tweet
#Infection rates are equal in #RWD #real #world #data using #biosimilars compared to previous use of #originators. BC database #0970 #ACR23 @RheumNow @ACRheum #arthritisresearchcanada #ARC https://t.co/eVSPgVfmQG
Obs study, bDMARDs & malignancy
TNFi w/lower risk than ABA/RTX/IL6i & numerically lower than JAKs
I'm a little skeptical... KM curves diverged w/~45 days, seems implausible?
Agree w/first author, possible channeling bias
@RheumNow #ACR23 Abstr 1678 https://t.co/1uL3j6kTSj
Richard Conway
Tweet
Sendaydiego et al. Comparative cancer safety b/tsDMARDs. 37,026 patient database cohort study. Compared to TNFi, RTX HR 2.2 (1.5, 3.3) ABA HR 1.7 (1.3-2.4), JAKi HR 1.3 (0.9-1.9). Abstr#1678 #ACR23 @RheumNow https://t.co/bTNtaNJrln https://t.co/qQBM2F2q8N
Aurelie Najm
Tweet
Ritux (OR 2.2), ABA (OR 1.3), JAKi (OR 1.3) significantly increase risk of cancer vs. TNFi
Cohort of 37000+ RA pts starting bio/tsDMARDs (379 incident cancers)
True biologic effect or confounding by indication in a generally more comorbid population?
@RheumNow #ACR23 ABST1678 https://t.co/suj6mVBEC0
Dr. Antoni Chan
Tweet
There was a lower hazard ratio for incident cancer with exposure to TNFi compared to non-TNFi (RTX and ABA) and JAKi. Limits: potential for residual confounding by indication and small number of outcomes per drug class, Xavier S, Abst#1678 #ACR23 @RheumNow https://t.co/vJpFwl6Ivj
Aurelie Najm
Tweet
RA-ILD: the study that exonerates TNFi ?
TNFi vs. other BioDMARDs/JAK do not increase risk of death or hospitalization over 1 and 3 yrs follow up.
No subgroups stand out
VHA cohort, 50% smokers
No info on ILD patterns or disease trajectory
ABST1582 @RheumNow #ACR23 https://t.co/frv16oRLqv
sheila
Tweet
Dr. AMendel et al:TMP-SMX prophylaxis assoc w⬇️serious infexns in RTX treated GPA pts; BL (aHR 0.5;95%CI 0.3-0.8) & time-varying exposure (aHR 0.5; 95%CI 0.3-0.9)
A good thing to consider but weigh benefits/harms w/TMP-SMX prophy. More studies req'd?
#ACR23 ABST1584 @RheumNow https://t.co/dfsfpcQu2A
Dr. Rachel Tate
Tweet
Izokibep, IL-17Ai, #ACR23 abs #1688 demonstrated ACR70 in 52%, PASI100 in 71% and enthesitis complete resolution in 89% at week 46. Well tolerated, no dose-related AEs, similar safety with other IL-17Ai https://t.co/TQAIVa9H2j @rheumnow https://t.co/ihzxnuAsWw
Richard Conway
Tweet
Non TNFi b/tsDMARDs vs TNFi in RA-ILD. New-User, Propensity Score Matched Study. 454 patients. No difference! resp-related hospitalisation aHR 1.22 [0.92, 1.60] No difference mortality. Abstr#1582 #ACR23 #ACRbest @RheumNow https://t.co/HzzVo9dJHi https://t.co/mZuHq4GShU
Eric Dein
Tweet
Upcoming Plenary II session
Ab#1584 on Bactrim for GPA pts on RTX
Should you use this for prophylaxis after weaning the prednisone?
#ACR23 @RheumNow
